榮泰健康(603579.SH):募投項目“廠房新建項目”延期
格隆匯12月8日丨榮泰健康(603579.SH)公佈,公司募投項目“廠房新建項目”旨在通過擴大生產能力、提升產品質量控制和改進生產工藝,將現有的按摩器具產品進一步做大做強,進一步提高公司效益。
截至本公告日,累計已投入募集資金金額1.598億元,投入進度79.23%,截至期末累計投入金額與承諾投入金額的差額4190.50萬元。項目原計劃截止日期為2020年12月。
目前,該項目廠房建築結構工程已完成,生產設備進入安裝調試過程中。根據目前建設進展,公司經過慎重研究,擬將“廠房新建項目”實施週期延長至2021年3月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.